本文關鍵詞：莫西沙星超短程治療初治菌陽肺結核患者的療效與安全性　出處：《中國醫(yī)藥指南》2017年04期 　論文類型：期刊論文

  更多相關文章： 莫西沙星 超短程治療 初治菌陽肺結核 臨床療效

【摘要】：目的分析探討莫西沙星超短程治療初治菌陽肺結核患者的療效與安全性。方法選2012年4月至2015年7月來我院接受初治菌陽肺結核的120例患者,分為對照組和實驗組兩組,每組60例患者,實驗組患者采用莫西沙星超短程治療方案進行治療,對照組患者采用常規(guī)治療方案進行治療,所有患者均獲得隨訪。結果在治療后7周,實驗組患者中出現(xiàn)痰結核菌轉(zhuǎn)陰的有56例,對照組患者中出現(xiàn)痰結核菌轉(zhuǎn)陰的有42例,治療10周后,實驗組和對照組患者中出現(xiàn)痰結核菌轉(zhuǎn)陰的患者分別為58、44例,兩組之間比較,差異顯著,具有統(tǒng)計學意義(P0.05)。結論莫西沙星超短程治療初治菌陽肺結核患者的臨床效果顯著,能夠有效的改善患者的臨床癥狀,并且莫西沙星藥物使用安全可靠,值得臨床推廣和使用。
[Abstract]:Objective to analyze the efficacy and safety of moxifloxacin in the treatment of primary bacterial positive pulmonary tuberculosis. Methods 120 cases of newly treated positive pulmonary tuberculosis from April 2012 to July 2015 in our hospital were selected. The patients in the experimental group were treated with moxifloxacin ultrashort therapy, and the patients in the control group were treated with routine therapy. Results at 7 weeks after treatment, 56 cases of sputum tuberculosis turned negative in the experimental group and 42 cases in the control group, 10 weeks after treatment. In the experimental group and the control group, the number of patients with sputum tuberculous bacilli turning negative was 58.44 cases, the difference between the two groups was significant. Conclusion moxifloxacin ultrashort treatment of patients with bacterial positive pulmonary tuberculosis has a significant clinical effect, can effectively improve the clinical symptoms of patients. The use of moxifloxacin is safe and reliable and worthy of clinical promotion and use.
【作者單位】： 阜新市傳染病醫(yī)院;
【分類號】：R521
【正文快照】： 近年來,我國肺結核的發(fā)病率越來越高,而現(xiàn)在治療肺結核的藥物主要為喹諾酮類藥物[1],該類藥物具有較高的抗結核活性,并且在臨床上得到廣泛的應用。但是對于肺結核的治療方案,臨床上卻沒有更為明確的方案[2]。本次研究2012年4月至2015年7月來我院接受初治菌陽肺結核的120例患者

【參考文獻】

相關期刊論文 前6條

1 漆l，

本文編號：1406015